What is Modulight Bio?
Modulight Bio is a biotechnology innovator specializing in the development of a precision neuromodulation platform. By utilizing optogenetics, the company aims to provide fast-acting, highly specific relief for patients suffering from debilitating conditions such as seizures, tremors, and neuropathic pain. The firm is currently prioritizing trigeminal neuropathic pain as its primary indication for upcoming clinical studies.
The company's market position is defined by its unique ability to harness light-based technology to modulate neural activity. This approach represents a significant departure from conventional therapies, offering the potential for improved patient outcomes and a more refined therapeutic profile. By focusing on high-impact neurological challenges, Modulight Bio is positioning itself as a key player in the evolving landscape of neuro-technology and precision therapeutics.
How much funding has Modulight Bio raised?
Modulight Bio has raised a total of $12.2M across 1 funding round:
Seed
$12.2M
Seed (2025): $12.2M with participation from SilverArc Capital, Secret Chord Ventures, Jibe Ventures, LocalGlobe, and Sara Capital
Key Investors in Modulight Bio
SilverArc Capital
SilverArc Capital is an investment management firm that specializes in the healthcare sector, providing tailored financial solutions to support complex industry needs.
Secret Chord Ventures
Secret Chord Ventures is an Israel-based early-stage venture firm that invests in exceptional entrepreneurs aiming to create category-defining companies through close advisory relationships.
Jibe Ventures
Jibe Ventures is an early-stage venture capital fund that leverages the founder-operator experience of its team to provide strategic support in team building and go-to-market execution.
What's next for Modulight Bio?
With the recent capital secured, Modulight Bio is poised to advance its lead candidate into critical clinical trials. The strategic roadmap involves rigorous validation of its optogenetic platform, ensuring safety and efficacy in human subjects. Future growth will likely center on expanding the company's intellectual property portfolio and establishing partnerships with clinical research organizations to streamline the path to regulatory approval.
The company's trajectory suggests a focus on scaling its operational capabilities to support multi-site clinical investigations. As it moves forward, Modulight Bio will likely continue to attract interest from institutional investors focused on the intersection of biotechnology and medical device innovation, further solidifying its role as a pioneer in the treatment of chronic neurological disorders.
